by Truveta Research | Sep 5, 2025 | Research, Research Insights
AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025 after the CVS GLP-1 formulary change. In contrast, AOM semaglutide increased by +0.1 points...
by Truveta Research | Jul 24, 2025 | Research
Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
by Truveta Research | Jul 14, 2025 | Research, Research Insights
In 2023, the American Academy of Pediatrics (AAP) released groundbreaking new guidelines recommending early treatment for childhood and adolescent obesity—including the use of medications for weight management in adolescents and cautioning against the common practice...
by Truveta Research | Jun 13, 2025 | Research, Research Insights
Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with...
by Truveta Research | Apr 18, 2025 | Research, Research Insights
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in March 2025 increased relative to December 2024 (+12.96%). Anti-diabetic medication (ADM) prescribing increased from December 2024 to January 2025, then remained relatively stable until March...
